Seaport Therapeutics, Inc. Common Stock (SPTX NASDAQ) stock market data APIs
$22.0909
0.92(4.2%)
as of September 16, 2026
Try our APIs with
free plan!
Seaport Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.
Prev. Close
22.0909
Open
23.0107
High
24.4501
Low
21.8013
52 wk Range
0.01-28.38
Market Cap
1 229 M
Shares Outstanding
53 531 K
EPS
-1.78
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Seaport Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Seaport Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Seaport Therapeutics, Inc. Common Stock Fundamental Data
Seaport Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -143 751 008
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Seaport Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-03
- EPS/Forecast: -0.71
Get Seaport Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Seaport Therapeutics, Inc. Common Stock News
New
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
BOSTON, August 31, 2026--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsyc...
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls ...
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
Quick Read SPTX's Glyph prodrug platform has generated 24 candidates, with lead asset GlyphAllo entering Phase 2b for MDD and topline results expected in 1H 2027. BMY previously paid $14 billion for ...
Seaport Therapeutics Reports Wider Net Loss In Q1; Expects Phase 2b BUOY-1 Trial Data In H1,2027
(RTTNews) - Seaport Therapeutics, Inc. (SPTX), reported a wider net loss for its first financial quarter ended March 31, 2026, and provided near term milestone update. Company Profile Seaport Therap...
Get Seaport Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
